Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
F0024 / Shanghai Fudan-Zhangjiang
NCT06519370: FDA018-ADC Vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer	Recruiting	3	350	RoW	FDA018-ADC, FDA018-Antibody-drug Conjugate, Eribulin, Halaven, Capecitabine, Xeloda, Gemcitabine, Gemzar, Vinorelbine, Navelbine	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.	Triple Negative Breast Cancer	08/26	06/27
F0024-101, NCT05174637: A Study of FDA018-ADC in Patients With Advanced Solid Tumors	Recruiting	1	78	RoW	FDA018-ADC, FDA018-Antibody-drug Conjugate	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.	Advanced/ Metastatic Solid Tumors	12/29	12/29